Shweta Sharma, Sunil, KP Kochhar* and Suman Jain

Department of Physiology, All India Institute of Medical Sciences, New Delhi, India

*Corresponding Author: KP Kochhar, Professor, Department of Physiology, All India Institute of Medical Sciences, New Delhi, India.

Received: October 21, 2021; Published: November 09, 2021

Abstract

Parkinson’s disease (PD) is one of the most significant medical and social burdens of our time. It is a multifactorial neurodegenerative disorder, affecting 3.7% of the population over 65 years of age. PD involves degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNPC) with deficiency of dopamine. Anxiety is frequent in Parkinson’s disease (PD) and has a negative impact on disease symptoms and quality of life. The underlying mechanisms remain largely unknown. Several evidences provide support for involvement of the microbiota-gut-brain axis in PD pathogenesis. In this review, we intend to provide a comprehensive overview of current knowledge on how cognitive behavior deficit occur in PD, and its potential as a new target of therapeutic interventions for PD.

Keywords: Anxiety; Dopamine; Gastrointestinal; Microbiota; Pars Compacta; Pathophysiology

References

1. Banks GT., et al. “TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander”. Mammalian Genome5 (2008): 299-305.
2. Barcia C., et al. “Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian”. Journal of Neural Transmission9 (2005): 1237-1248.
3. Boveri M., et al. “Highly purified lipoteichoic acid from gram-positive bacteria induces in vitro blood-brain barrier disruption through glia activation: role of pro-inflammatory cytokines and nitric oxide”. Neuroscience4 (2006): 1193-1209.
4. Bradaric BD., et al. “Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy”. Journal of Neural Transmission1 (2012): 59-71.
5. Braniste V., et al. “The gut microbiota influences blood-brain barrier permeability in mice”. Science Translational Medicine 263 (2014): 263ra158-263ra158.
6. Cabezas R., et al. “Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease”. Frontiers in Cellular Neuroscience 8 (2014): 211.
7. Cantu-Jungles TM., et al. “Potential of prebiotic butyrogenic fibers in Parkinson's disease”. Frontiers in Neurology 10 (2019): 663.
8. Dong XL., et al. “Polymannuronic acid prevents dopaminergic neuronal loss via brain-gut-microbiota axis in Parkinson's disease model”. International Journal of Biological Macromolecules 164 (2020): 994-1005.
9. Farkas E., et al. “Pathological features of cerebral cortical capillaries are doubled in Alzheimer’s disease and Parkinson’s disease”. Acta Neuropathologica4 (2000): 395-402.
10. Fasano A., et al. “Gastrointestinal dysfunction in Parkinson's disease”. The Lancet Neurology6 (2015): 625-639.
11. Faucheux BA., et al. “Blood vessels change in the mesencephalon of patients with Parkinson's disease”. Lancet 9157 (1999): 981-982.
12. Goldstein LH and Mellers JDC. “Psychologic treatment of functional neurologic disorders”. Handbook of Clinical Neurology 139 (2016): 571-583.
13. Gratwicke J., et al. “Parkinson’s disease dementia: a neural networks perspective”. Brain 6 (2015): 1454-1476.
14. Hirano S., et al. “Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease”. Journal of Neuroscience16 (2008): 4201-4209.
15. Hoyles L., et al. “Microbiome-host systems interactions: protective effects of propionate upon the blood-brain barrier”. Microbiome1 (2018): 1-13.
16. Janelidze S., et al. “Increased CSF biomarkers of angiogenesis in Parkinson disease”. Neurology21 (2015): 1834-1842.
17. Jangula A and Murphy EJ. “Lipopolysaccharide-induced blood brain barrier permeability is enhanced by alpha-synuclein expression”. Neuroscience Letters 551 (2013): 23-27.
18. Jankovic J. “Parkinson’s disease: clinical features and diagnosis”. Journal of Neurology, Neurosurgery and Psychiatry 4 (2008): 368-376.
19. Jost WH. “Gastrointestinal motility problems in patients with Parkinson’s disease”. Drugs and Aging4 (1997): 249-258.
20. Kortekaas R., et al. “Blood-brain barrier dysfunction in parkinsonian midbrain in vivo”. Annals of Neurology2 (2005): 176-179.
21. Krajewska M., et al. “Tumor-associated alterations in caspase-14 expression in epithelial malignancies”. Clinical Cancer Research 11 (2005): 5462-5471.
22. Kurkowska-Jastrzębska I., et al. “The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse”. Experimental Neurology1 (1999): 50-61.
23. Lei E., et al. “Fatty acids and their therapeutic potential in neurological disorders”. Neurochemistry International 95 (2016): 75-84.
24. Liebner S., et al. “Wnt/β-catenin signaling controls development of the blood-brain barrier”. Journal of Cell Biology3 (2008): 409-417.
25. Liu J., et al. “The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: A meta-analysis of randomized controlled trials”. Journal of Affective Disorders 245 (2019): 98-112.
26. Liu J., et al. “Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1”. Journal of the Neurological Sciences 381 (2017): 176-181.
27. Logsdon AF., et al. “Gut reactions: How the blood-brain barrier connects the microbiome and the brain”. Experimental Biology and Medicine2 (2018): 159-165.
28. Mayerhofer R., et al. “Diverse action of lipoteichoic acid and lipopolysaccharide on neuroinflammation, blood-brain barrier disruption, and anxiety in mice”. Brain behavior and immunity 60 (2017): 174-187.
29. Montagne A., et al. “Blood-brain barrier breakdown in the aging human hippocampus”. Neuron2 (2015): 296-302.
30. Nankova BB., et al. “Enteric bacterial metabolites propionic and butyric acid modulate gene expression, including CREB-dependent catecholaminergic neurotransmission, in PC12 cells-possible relevance to autism spectrum disorders”. PLoS One8 (2014): e103740.
31. Ohlin KE., et al. “Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia”. Brain8 (2011): 2339-2357.
32. Park MJ and Sohrabji F. “The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats”. Journal of Neuroinflammation1 (2016): 1-14.
33. Perez F., et al. “Risk of dementia in an elderly population of Parkinson's disease patients: a 15-year population-based study”. Alzheimer's and Dementia6 (2012): 463-469.
34. Scheperjans F., et al. “Gut microbiota are related to Parkinson's disease and clinical phenotype”. Movement Disorders 3 (2015): 350-358.
35. Sheen TR., et al. “Penetration of the blood-brain barrier by Staphylococcus aureus: contribution of membrane-anchored lipoteichoic acid”. Journal of Molecular Medicine6 (2010): 633-639.
36. Sun Y., et al. “Recombinant adenovirus-mediated intestinal trefoil factor gene therapy for burn-induced intestinal mucosal injury”. PLoS One4 (2013): e62429.
37. Sweeney M.D., et al. “Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders”. Nature Reviews Neurology3 (2018): 133-150.
38. Unger MM., et al. “Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls”. Parkinsonism & Related Disorders 32(2016): 66-72.
39. Van Dessel N., et al. “Non‐pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults”. Cochrane Database of Systematic Reviews 11 (2014).
40. Wen J., et al. “Gut microbiome improves postoperative cognitive function by decreasing permeability of the blood-brain barrier in aged mice”. Brain Research Bulletin 164 (2020): 249-256.
41. Westin JE., et al. “Endothelial proliferation and increased bloodbrain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia”. The Journal of Neuroscience 37 (2006): 9448-9461.
42. Willis AW., et al. “Predictors of survival in patients with Parkinson disease”. Archives of Neurology5 (2012): 601-607.
43. Wong D., et al. “Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier”. Experimental Neurology 190 (2004): 446-455.
44. Wu XL., et al. “Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson’s disease”. Journal of Molecular Neuroscience1 (2014): 1-9.
45. Yang S., et al. “Anesthesia and surgery impair blood-brain barrier and cognitive function in mice”. Frontiers in Immunology 8 (2017): 902.
46. Yasuda T., et al. “Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease”. Experimental Neurology 2 (2007): 308-317.
47. Zhang SX., et al. “Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy”. Journal of Molecular Endocrinology 1 (2006): 1-12.
48. Zhao C., et al. “TNF-α knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice”. Neurobiology of Disease1 (2007): 36-46.

Citation

Citation: KP Kochhar., et al. “A Review on Cognitive Impairments in Parkinson’s Disease". Acta Scientific Veterinary Sciences 3.12 (2021): 27-32.

Copyright

Copyright: © 2021 KP Kochhar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.